Cas9 Stable Cell Line - Jurkat, Clone E6-1

The Jurkat, Clone E6-1 cell line is a mature human T lymphocyte line originally derived from the peripheral blood of a 14-year-old male with T-cell leukemia. This immortalized cell line exhibits characteristics of immature T cells, expressing CD3 and CD4 markers but not CD8. It grows vigorously in suspension culture, responds to T cell activators such as phytohemagglutinin (PHA), and demonstrates good reproducibility, making it a cornerstone of immunology, oncology, and HIV research. The Cas9 Stable Cell Line - Jurkat, Clone E6-1 is further developed through transduction of stably expressed Cas9 nuclease. This genetically engineered variant achieves precise, programmable genome editing while maintaining the growth kinetics and phenotypic characteristics of the parent cell line. Stable Cas9 expression eliminates the need for repeated transfections, ensuring consistent editing efficiency during passage and reducing experimental errors.

In functional genomics, Cas9 Stable Cell Line - Jurkat, Clone E6-1 enables high-throughput CRISPR screening to identify genes regulating T-cell activation, cytokine production, and immune checkpoint pathways, thereby accelerating drug target discovery for autoimmune diseases and cancer. Oncology researchers use it to mimic T-cell leukemia mutations (e.g., NOTCH1 or PTEN knockout) and investigate chemotherapy resistance mechanisms. In immunotherapy development, it helps knock out genes such as PD-1 or CTLA-4 to enhance the efficacy of CAR-T cells or study immune escape mechanisms. Infectious disease research uses it to elucidate host factors in viral infections (e.g., studying HIV invasion by knocking out CCR5) or to construct reporter gene cell lines for pathogen lifecycle monitoring. Compared to transient CRISPR systems, this stable cell line offers superior reproducibility, making it suitable for long-term studies such as tumor xenograft models or chronic toxicity trials, thus becoming an essential tool for preclinical validation of gene therapy and immunomodulatory drugs.